Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 1.1% – Here’s Why

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) traded down 1.1% on Tuesday . The company traded as low as $12.35 and last traded at $13.32. 357,987 shares traded hands during trading, a decline of 41% from the average session volume of 604,027 shares. The stock had previously closed at $13.47.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a research note on Monday, February 10th. They issued a “sell” rating for the company.

Tonix Pharmaceuticals Stock Performance

The company has a fifty day moving average price of $21.24 and a two-hundred day moving average price of $20.57. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The company has a market capitalization of $25.47 million, a P/E ratio of 0.00 and a beta of 2.23.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Two Sigma Investments LP acquired a new position in shares of Tonix Pharmaceuticals during the fourth quarter worth $66,000. Point72 Asset Management L.P. acquired a new stake in shares of Tonix Pharmaceuticals in the fourth quarter valued at about $526,000. Jane Street Group LLC raised its position in shares of Tonix Pharmaceuticals by 5,932.3% during the fourth quarter. Jane Street Group LLC now owns 1,662,682 shares of the company’s stock worth $548,000 after acquiring an additional 1,635,119 shares during the last quarter. Northern Trust Corp acquired a new position in shares of Tonix Pharmaceuticals in the fourth quarter worth approximately $162,000. Finally, Geode Capital Management LLC increased its position in Tonix Pharmaceuticals by 1,600.1% during the 4th quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company’s stock valued at $650,000 after purchasing an additional 1,855,907 shares during the period. 82.26% of the stock is owned by institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.